This company is the least transparent I've ever be
Post# of 30027
(Total Views: 491)
Posted On: 06/25/2018 11:58:42 AM
This company is the least transparent I've ever been involved with by far, but there are a couple things we know that I think are interesting:
They kept the valuation for Elto confidential until they announced they were considering a "business combination" with another company. My theory is they they used the 3rd party valuation somehow in determining how to structure the deal. I'm certainly not expecting them to get $158 million in equity in another company (half of $316k), but I'm sure the super high valuation certainly helped us in the negotiations. I'm guessing they had some kind of exclusivity period for the negotiations and the other party may have even helped pay for the valuation.
They are pursuing more data for Lympro. Normally I wouldn't think anything of this- any company would want to do this, but AMBS is so mismanaged and so broke, I just don't think they would be analyzing data from a trial when they didn't even have an office a couple months ago and they are 30 million is debt. I think they are getting a little ahead of themselves, so I think they are putting this data together either for an investor(s) or a partner. They also haven't formed a sub yet for the diagnostics, so there may be a reason why in whatever structure plan they are working on.
They kept the valuation for Elto confidential until they announced they were considering a "business combination" with another company. My theory is they they used the 3rd party valuation somehow in determining how to structure the deal. I'm certainly not expecting them to get $158 million in equity in another company (half of $316k), but I'm sure the super high valuation certainly helped us in the negotiations. I'm guessing they had some kind of exclusivity period for the negotiations and the other party may have even helped pay for the valuation.
They are pursuing more data for Lympro. Normally I wouldn't think anything of this- any company would want to do this, but AMBS is so mismanaged and so broke, I just don't think they would be analyzing data from a trial when they didn't even have an office a couple months ago and they are 30 million is debt. I think they are getting a little ahead of themselves, so I think they are putting this data together either for an investor(s) or a partner. They also haven't formed a sub yet for the diagnostics, so there may be a reason why in whatever structure plan they are working on.
(2)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼